Myopridin (Pridinol Mesilate)

Pridinol mesilate is believed to act on the central nervous system, decreasing the excitability of spinal motor neurons and modulating neurotransmitter activity. This central action lowers muscle tone, helping to alleviate spasm and associated discomfort, although the exact molecular mechanism is not fully defined.

The dosage of Myopridin is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. The prescriber will select the appropriate amount and frequency of intramuscular injection according to clinical guidelines.

Safety data for Pridinol mesilate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Myopridin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Myopridin (Pridinol mesilate) is an injectable muscle relaxant that acts centrally, similar to other agents such as baclofen or tizanidine. Compared with oral options, its intramuscular route can provide rapid onset, but the choice depends on clinical context, patient tolerance, and physician preference.

Myopridin should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

Myopridin is supplied as a sterile solution for intramuscular injection. A qualified healthcare professional administers the dose into a muscle, typically the deltoid or gluteal region, following aseptic technique and according to the prescriber’s instructions.

Serious risks include allergic reactions such as rash, swelling, or anaphylaxis, hepatic dysfunction indicated by elevated liver enzymes or jaundice, and cardiac arrhythmias. Patients should be monitored for these events, and treatment should be discontinued if they occur.

Myopridin is contraindicated in individuals with known hypersensitivity to Pridinol mesilate or any excipients in the formulation. Caution is advised for patients with severe hepatic or renal impairment, uncontrolled cardiovascular disease, or those taking interacting CNS depressants without close monitoring.